4-((5-(三氟甲基)吡啶-2-基)氧基)苯甲醛 | 103962-21-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-((5-(三氟甲基)吡啶-2-基)氧基)苯甲醛
• 英文名称: 4-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzaldehyde
• 英文别名: 4-[{5-(trifluoromethyl)pyridin-2-yl}oxy]benzaldehyde；4-(5-trifluoromethylpyridin-2-yloxy)benzaldehyde；4-{[5-(Trifluoromethyl)pyridin-2-yl]oxy}benzaldehyde；4-[5-(trifluoromethyl)pyridin-2-yl]oxybenzaldehyde
• CAS: 103962-21-6
• 化学式: C₁₃H₈F₃NO₂
• mdl: MFCD10703517
• 分子量: 267.207
• InChiKey: HIAPYMWYTXDSDE-UHFFFAOYSA-N

物化性质

• 沸点：
  347.9±42.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-((5-(三氟甲基)吡啶-2-基)氧基)苯甲醛 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 2-[4-(bromomethyl)phenoxy]-5-(trifluoromethyl)-pyridine
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not sulfonamide) were well tolerated in vitro, and the hydrophilic linkers provided some solubility improvements, particularly in combination with pyridine rings. Most of the 18 compounds further assessed showed high microsomal stabilities, although in the acute infection mouse model, just one stilbene (6-fold) and two pyridine-containing acetylene derivatives (5-fold and >933-fold) gave in vivo efficacies notably superior to the clinical stage compound pretomanid (PA-824). The most efficacious analogue also displayed outstanding in vivo activity in the stringent chronic model (up to 24-fold better than the drug delamanid and 4-fold greater than our previous best phenylpyridine candidate), with favorable pharmacokinetics, including good oral bioavailability in the rat.

  DOI：

  10.1021/jm501608q
• 作为产物：
  描述：

  对羟基苯甲醛 、 2-氟-5-三氟甲基吡啶 在 potassium carbonate 、 盐酸 作用下， 以 二甲基亚砜 、 水 为溶剂， 反应 24.5h， 以70%的产率得到4-((5-(三氟甲基)吡啶-2-基)氧基)苯甲醛
  参考文献：
  名称：

  发现甘氨酸磺酰胺作为sn -1-二酰基甘油脂肪酶α和α/β-羟化酶结构域6的双重抑制剂

  摘要：

  锡-1-二酰基甘油脂肪酶α（DAGL-α）是负责在中枢神经系统中产生内源性大麻素2-花生四烯酸甘油酯的主要酶。甘氨酸磺酰胺最近通过高通量筛选活动被鉴定为该酶的新型抑制剂。在这里，我们报道了基于活性蛋白轮廓分析（ABPP）的甘氨酸磺酰胺抑制剂及其在脑膜蛋白组全选择性对丝氨酸水解酶的首次结构-活性关系研究。我们发现（i）DAGL-α可耐受多种联芳基取代基，（ii）磺酰胺是诱导2，2-二甲基苯并二氢吡喃取代基的特定取向所必需的，并且（iii）羧酸对于其活性是必不可少的。ABPP透露，磺酰胺甘氨酸抑制剂具有至少三个脱靶点，包括α/β水解酶结构域6（ABHD6）。最后，我们将LEI-106确定为有效的DAGL-α/ ABHD6双重抑制剂，这使该化合物成为发现饮食引起的肥胖和代谢综合征的新分子疗法的潜在先导。

  DOI：

  10.1021/jm500681z

文献信息

• Synthesis and Bioactivities of Novel Pyrazole Oxime Derivatives Containing a 5-Trifluoromethylpyridyl Moiety
  作者：Hong Dai、Jia Chen、Hong Li、Baojiang Dai、Haibing He、Yuan Fang、Yujun Shi

  DOI：10.3390/molecules21030276

  日期：——

  in order to find novel biologically active pyrazole oxime compounds, a series of pyrazole oxime derivatives containing a 5-trifluoromethylpyridyl moiety were synthesized. Preliminary bioassays indicated that most title compounds were found to display good to excellent acaricidal activity against Tetranychus cinnabarinus at a concentration of 200 μg/mL, and some designed compounds still showed excellent

  在这项研究中，为了找到新型的具有生物活性的吡唑肟化合物，合成了一系列含有5-三氟甲基吡啶基部分的吡唑肟衍生物。初步的生物分析表明，发现大多数标题化合物在200μg/ mL的浓度下对朱砂叶螨具有良好的杀螨活性，而某些设计的化合物在10μg/ mL的浓度下仍对朱砂叶螨具有优良的杀螨活性。因为化合物8e，8f，8l，8m，8n，8p和8q的抑制率均为100.00％。有趣的是，一些目标化合物在200μg/ mL的浓度下对小菜蛾和蚜虫具有中等至良好的杀虫活性。此外，
• [EN] PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2<br/>[FR] COMPOSÉS DE PYRIMIDINONE UTILES DANS LE TRAITEMENT DE MALADIES OU D'ÉTATS PATHOLOGIQUES INDUITS PAR LA LP-PLA2
  申请人：GLAXO GROUP LTD

  公开号：WO2012076435A1

  公开（公告）日：2012-06-14

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

  本发明涉及抑制Lp-PLA2活性的新化合物，其制备方法，含有这些化合物的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿。
• [EN] PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE<br/>[FR] DÉRIVÉS DE PYRIMIDINE COMME ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010015653A1

  公开（公告）日：2010-02-11

  Disclosed are compounds of formula (I) and or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in the manufacture of a medicament for teating cardiovascular diseases, and processes for their preparation.

  揭示了公式（I）的化合物及其盐，这些化合物激活可溶性鸟苷酸环化酶（sGC），包含它们的药物组合物，它们在制造用于治疗心血管疾病的药物中的应用，以及它们的制备方法。
• [EN] 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE 3,5-DIAMINOPYRAZOLE KINASE
  申请人：AXIKIN PHARMACEUTICALS INC

  公开号：WO2013138613A1

  公开（公告）日：2013-09-19

  Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.

  本文提供了3,5-二氨基吡唑类化合物，例如，Formula IA中的化合物，用于调节COPD激酶活性，并提供了其药物组合物。本文还提供了它们的使用方法，用于治疗、预防或缓解RC激酶介导的疾病、疾病或症状之一。
• [EN] 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES<br/>[FR] BACTÉRICIDES À BASE DE 6,7-DIHYDROIMIDAZO [2,1-B][1,3] OXAZINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012141338A1

  公开（公告）日：2012-10-18

  The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof, wherein R1 represents tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrobenzoazepinyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolinyl, naphthyl, quinolyl, phenyl, biphenylyl, or pyridyl, these groups being optionally substituted, the phenyl, biphenylyl, and pyridyl represented by R1 each being substituted directly or via a linker with at least one group selected from the group consisting of tetrahydropyridyl, diazepanyl, diazabicycloheptanyl, tetrahydrotriazolopyrazinyl, tetrahydroimidazopyrazinyl, azabicyclooctanyl, oxazolyl, piperazinyl, piperidyl, thiazolyl, and the like, each of these groups being optionally substituted; and R2 represents hydrogen or lower alkyl. The present invention further provides a pharmaceutical composition containing the above.

  本发明提供了一种新型的6,7-二氢咪唑[2,1-b][1,3]噁嗪化合物，该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型抗酸杆菌具有优异的杀菌作用。具体而言，本发明提供了一种由式(1)表示的化合物或其盐，其中R1代表四氢异喹啉基、四氢喹啉基、四氢苯并氮杂环庚基、苯并噁唑基、苯并噻唑基、吲哚基、异吲哚啉基、萘基、喹啉基、苯基、联苯基或吡啶基，这些基团可选地被取代，其中R1表示的苯基、联苯基和吡啶基通过连接基直接或经过至少一种从四氢吡啶基、二氮杂环庚基、二氮杂双环庚基、四氢三唑吡嗪基、四氢咪唑吡嗪基、氮杂双环辛基、噁唑基、哌嗪基、哌啶基、噻唑基等基团中选取的至少一种基团进行取代，这些基团可选地被取代；R2代表氢或低碳基。本发明还提供了包含上述化合物的药物组合物。